ImmunityBio, BeiGene launch Phase 3 Trial to advance lung cancer immunotherapy

ImmunityBio, Inc. (NASDAQ: IBRX) has entered into a collaboration and supply agreement with BeiGene, Ltd., a global oncology company, to initiate a confirmatory Phase 3 ... Read More